{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '115', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'date of last known contact. The analysis using the restricted mean survival time method may', 'be conducted for os to account for the possible nonproportional hazards effect.', '9.6.1.3', 'Objective Response Rate', 'The stratified Miettinen and Nurminen method will be used for comparison of ORR between', 'the treatment groups. The difference in ORR and its 95% CI from the stratified Miettinen and', 'Nurminen method with strata weighting by sample size will be provided.', '9.6.1.4', 'Duration of Response', 'For participants who demonstrate CR or PR, DOR is defined as the time from first', 'documented evidence of CR or PR until PD or death due to any cause, whichever occurs', 'first.', 'The nonparametric Kaplan-Meier method will be used to summarize the DOR. The median', 'and range of DOR will be provided.', 'Censoring rules for DOR are summarized in Table 9.', 'Table 9 Censoring Rules for Duration of Response', 'Situation', 'Date of Progression or Censoring', 'Outcome', 'No PD or death, no new anticancer', 'Last adequate disease assessment', 'Censor', 'therapy initiated', '(nonevent)', 'No PD or death, new anticancer', 'Last adequate disease assessment before new', 'Censor', 'therapy initiated', 'anticancer therapy initiated', '(nonevent)', 'Death or PD immediately after >2', 'Earlier date of last adequate disease assessment', 'Censor', 'consecutive missed disease', 'before >2 missed adequate disease assessments', '(nonevent)', 'assessments or after new anticancer', 'and new anticancer therapy, if any', 'therapy, if any', 'Death or PD after 1 missed disease', 'PD or death', 'End of response', 'assessments and before new', '(event)', 'anticancer therapy, if any', 'Abbreviation: PD = progressive disease.', 'Note: A missed disease assessment includes any assessment that is not obtained or is considered inadequate for', 'evaluation of response.', '9.6.2', 'Statistical Methods for Safety Analyses', 'Safety and tolerability will be assessed by clinical review of all relevant parameters including', 'AEs, laboratory tests, vital signs, and ECG measurements.', 'The analysis of safety results will follow a tiered approach (Table 10). The tiers differ with', 'respect to the analyses that will be performed. AEs (specific terms as well as system organ', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '116', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'class terms) and events that meet predefined limits of change in laboratory, vital signs, and', 'ECG parameters are either prespecified as \"Tier 1\" endpoints or will be classified as', 'belonging to \"Tier 2\" or \"Tier 3,\" based on observed proportions of participants with an', 'event.', 'Tier 1 Events', 'Safety parameters or AEs of special interest that are identified a priori constitute \"Tier 1\"', 'safety endpoints that will be subject to inferential testing for statistical significance. AEs that', 'are immune-mediated or potentially immune-mediated are well documented and will be', 'evaluated separately; however, these events have been characterized consistently throughout', 'the pembrolizumab clinical development program, and determination of statistical', 'significance is not expected to add value to the safety evaluation. Similarly, the combination', 'of pembrolizumab and lenvatinib has not been associated with any new safety signals.', 'Finally, there are no known AEs associated with participants with NSCLC for which', 'determination of a p value is expected to impact the safety assessment. Therefore, there are', 'no Tier 1 events for this protocol.', 'Tier 2 Events', 'Tier 2 parameters will be assessed via point estimates with 95% CIs provided for differences', 'in the proportion of participants with events using the Miettinen and Nurminen method, an', 'unconditional, asymptotic method [Miettinen, O. 1985].', 'Membership in Tier 2 requires that at least 10% of participants in any treatment group exhibit', 'the event; all other AEs and predefined limits of change will belong to Tier 3. The threshold', 'of at least 10% of participants was chosen for Tier 2 events because the population', 'randomized in this study are in critical conditions and usually experience various AEs of', 'similar types regardless of treatment; events reported less frequently than 10% of participants', 'would obscure the assessment of the overall safety profile and add little to the interpretation', 'of potentially meaningful treatment differences. In addition, Grade 3 to 5 AEs (>5% of', 'participants in one of the treatment groups) and SAEs (>5% of participants in one of the', 'treatment groups) will be considered Tier 2 endpoints. Because many 95% CIs may be', 'provided without adjustment for multiplicity, the CIs should be regarded as a helpful', 'descriptive measure to be used in safety review, not a formal method for assessing the', 'statistical significance of the between-group differences.', 'Tier 3 Events', 'Safety endpoints that are not Tier 1 or 2 events are considered Tier 3 events. Only point', 'estimates by treatment group are provided for Tier 3 safety parameters.', 'Continuous Safety Measures', 'For continuous measures such as changes from baseline in laboratory, vital signs, and ECG', 'parameters, summary statistics for baseline, on-treatment, and change from baseline values', 'will be provided by treatment group in table format.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}